Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aytu Biopharma Inc (AYTU)

Aytu Biopharma Inc (AYTU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,785
  • Shares Outstanding, K 25,171
  • Annual Sales, $ 27,630 K
  • Annual Income, $ -13,620 K
  • 60-Month Beta -0.28
  • Price/Sales 0.75
  • Price/Cash Flow N/A
  • Price/Book 0.61
Trade AYTU with:

Options Overview

Details
  • Implied Volatility 92.35%
  • Historical Volatility 41.09%
  • IV Percentile 13%
  • IV Rank 16.06%
  • IV High 171.76% on 08/19/21
  • IV Low 77.16% on 09/14/21
  • Put/Call Vol Ratio 0.04
  • Today's Volume 77
  • Volume Avg (30-Day) 81
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 2,955
  • Open Int (30-Day) 2,828

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.02 +3.64%
on 09/16/21
3.89 -19.54%
on 09/02/21
-0.30 (-8.75%)
since 08/17/21
3-Month
3.02 +3.64%
on 09/16/21
5.97 -47.57%
on 06/21/21
-1.85 (-37.15%)
since 06/17/21
52-Week
3.02 +3.64%
on 09/16/21
14.00 -77.64%
on 10/06/20
-10.67 (-77.32%)
since 09/17/20

Most Recent Stories

More News
Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome

Chaired by Dr. Hal Dietz and joined initially by Dr. Xavier Jeunemaitre, Dr. Shaine Morris, Dr. Bart Loeys, and Dr. Peter Byers with additional advisors to be added

AYTU : 3.13 (+3.30%)
SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm

National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Odonate Therapeutics, Inc., Aytu Biopharma, Inc., Eargo, Inc., and Corcept Therapeutics, Inc. ...

ODT : 3.00 (-6.54%)
AYTU : 3.13 (+3.30%)
EAR : 21.97 (+0.92%)
CORT : 20.51 (-0.58%)
Aytu BioPharma to Present at Upcoming September Investor Conferences

ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced...

AYTU : 3.13 (+3.30%)
AYTU : 3.13 (+3.30%)
Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus

ENGLEWOOD, CO / ACCESSWIRE / July 27, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced...

AYTU : 3.13 (+3.30%)
Implied Volatility Surging for Aytu Biopharma (AYTU) Stock Options

Investors need to pay close attention to Aytu Biopharma (AYTU) stock based on the movements in the options market lately.

AYTU : 3.13 (+3.30%)
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study

Results Indicate That Endotracheal UVA Light Catheter Therapy is Associated with Significant Reduction in SARS-CoV-2 Viral Load and Improvement in Clinical Outcomes in Mechanically Ventilated COVID-19...

AYTU : 3.13 (+3.30%)
Thinking about buying stock in Anavex Life Sciences, Globalstar, Rapt Therapeutics, Aytu Biopharma, or Evofem Biosciences?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, GSAT, RAPT, AYTU, and EVFM.

GSAT : 1.7700 (-1.12%)
EVFM : 0.8377 (+3.04%)
RAPT : 39.47 (+1.65%)
AVXL : 17.63 (+3.89%)
AYTU : 3.13 (+3.30%)
Aytu BioPharma to Present at Upcoming June Investor Conferences

ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced...

AYTU : 3.13 (+3.30%)
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights

NEOS : 1.1500 (-2.54%)
AYTU : 3.13 (+3.30%)
Aytu Biopharma, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 17, 2021 / Aytu Biopharma, Inc. (NASDAQ:AYTU) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on May 17, 2021 at 4:30 PM Eastern...

AYTU : 3.13 (+3.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual...

See More

Key Turning Points

3rd Resistance Point 3.30
2nd Resistance Point 3.22
1st Resistance Point 3.18
Last Price 3.13
1st Support Level 3.06
2nd Support Level 2.98
3rd Support Level 2.94

See More

52-Week High 14.00
Fibonacci 61.8% 9.81
Fibonacci 50% 8.51
Fibonacci 38.2% 7.21
Last Price 3.13
52-Week Low 3.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar